Spencer Carl Cleland, MD | |
2101 Charlotte St, Kansas City, MO 64108-2727 | |
(816) 404-3900 | |
(816) 404-3918 |
Full Name | Spencer Carl Cleland |
---|---|
Gender | Male |
Speciality | Student In An Organized Health Care Education/training Program |
Location | 2101 Charlotte St, Kansas City, Missouri |
Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
Identifier | Type | State | Issuer |
---|---|---|---|
1235767286 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207W00000X | Ophthalmology | 2021017479 (Missouri) | Secondary |
390200000X | Student In An Organized Health Care Education/training Program | (* (Not Available)) | Primary |
Mailing Address | Practice Location Address |
---|---|
Spencer Carl Cleland, MD 2101 Charlotte St, Kansas City, MO 64108-2727 Ph: (816) 404-3900 | Spencer Carl Cleland, MD 2101 Charlotte St, Kansas City, MO 64108-2727 Ph: (816) 404-3900 |
News Archive
"It's not brain surgery" is a phrase often uttered to dismiss a job's difficulty, but when the task actually is removing a brain tumor, even the slightest mistake could have serious health consequences. To help surgeons in such high-pressure situations, researchers from Prof. Adam Wax's team at Duke University's Fitzpatrick Institute for Photonics and Biomedical Engineering Department have proposed a way to harness the unique optical properties of gold nanoparticles to clearly distinguish a brain tumor from the healthy, and vital, tissue that surrounds it.
Military service exposes soldiers to a unique set of physical challenges, including toxic chemicals and traumatic brain injury, which can have profound effects on their health and well-being.
A political drive, led by the UK and US, to screen older people for minor memory changes (often called mild cognitive impairment or pre-dementia) is leading to unnecessary investigation and potentially harmful treatment for what is arguably an inevitable consequence of ageing, warn University of Sydney experts in in a paper published in the British Medical Journal today.
RaySearch Laboratories AB has entered into a long-term distribution agreement with Hitachi Medical Corporation based in Tokyo, Japan. The agreement means that Hitachi will be fully responsible for marketing, sales and service of RaySearch's proprietary treatment planning system RayStation® on the Japanese market from April 1, 2014.
› Verified 8 days ago